Follow
Diana Reyes Garau
Diana Reyes Garau
Postdoctoral researcher, Universitat Pompeu Fabra
Verified email at upf.edu
Title
Cited by
Cited by
Year
Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease
EB Swallow, D Reyes, NS Hopkinson, WDC Man, R Porcher, EJ Cetti, ...
Thorax 62 (2), 115-120, 2007
9042007
Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes
GP Vicent, AS Nacht, R Zaurin, J Font-Mateu, D Soronellas, F Le Dily, ...
Genes & development 27 (10), 1179-1197, 2013
892013
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases
A Borroto, D Reyes-Garau, MA Jiménez, E Carrasco, B Moreno, ...
Science translational medicine 8 (370), 370ra184-370ra184, 2016
522016
Co-evolution of the branch site and SR proteins in eukaryotes
M Plass, E Agirre, D Reyes, F Camara, E Eyras
Trends in genetics 24 (12), 590-594, 2008
512008
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
M Gonzalez-Santamarta, G Quinet, D Reyes-Garau, B Sola, G Roué, ...
Proteostasis and Disease: From Basic Mechanisms to Clinics, 153-174, 2020
372020
Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications
D Reyes-Garau, ML Ribeiro, G Roué
Cancers 11 (10), 1483, 2019
362019
Activation of mitogen-and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins
D Reyes, C Ballaré, G Castellano, D Soronellas, JR Bagó, J Blanco, ...
Oncogene 33 (12), 1570-1580, 2014
322014
R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes
P Mendoza, N Martínez-Martín, ER Bovolenta, D Reyes-Garau, ...
Science signaling 11 (532), eaal1506, 2018
302018
Recent advances in the targeting of epigenetic regulators in B-cell non-Hodgkin lymphoma
ML Ribeiro, D Reyes-Garau, M Armengol, M Fernández-Serrano, G Roué
Frontiers in genetics 10, 477950, 2019
252019
Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in patients with B-cell non–Hodgkin lymphoma
ML Ribeiro, D Reyes-Garau, M Vinyoles, N Profitós Pelejà, JC Santos, ...
Clinical Cancer Research 27 (23), 6591-6601, 2021
112021
NFAT5 amplifies antipathogen responses by enhancing chromatin accessibility, H3K27 demethylation, and transcription factor recruitment
G Lunazzi, M Buxade, M Riera-Borrull, L Higuera, S Bonnin, ...
The Journal of Immunology 206 (11), 2652-2667, 2021
92021
PS1310 the novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of UBLITUXIMAB-UMBRALISIB (U2) drug combination in preclinical models of B-NHL
ML Ribeiro, E Normant, DR Garau, HP Miskin, P Sportelli, MS Weiss, ...
HemaSphere 3 (S1), 598, 2019
92019
The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G protein-coupled …
E Normant, ML Ribeiro, N Profitos-Peleja, P Blecua, D Reyes-Garau, ...
Blood 138, 1196, 2021
82021
Constitutive activation of p62/Sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma
G Quinet, W Xolalpa, D Reyes-Garau, N Profitós-Pelejà, M Azkargorta, ...
Cancers 14 (4), 923, 2022
62022
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, D Reyes-Garau, ...
Frontiers in immunology 14, 1130052, 2023
12023
Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma
A Chamorro-Jorganes, ML Ribeiro, N Profitos-Peleja, D Reyes-Garau, ...
Cancer Research 80 (16_Supplement), 2925-2925, 2020
12020
TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle …
ML Ribeiro, M Armengol, M Vinyoles, D Reyes-Garau, ...
Immunology, 2205-2205, 2020
12020
Quadriceps strength predicts mortality in patients with chronic obstructive pulmonary disease
D Reyes, EB Swallow, E Cetti, A Moore, NS Hopkinson, M Khan, ...
Thorax 60, II49-II49, 2005
12005
GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity
ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, DR Garau, ...
bioRxiv, 2022.03. 31.486558, 2022
2022
Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma
ML Ribeiro, D Reyes-Garau, M Vinyoles, NP Pelejà, JC Santos, ...
Hematological Oncology 39, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20